Results 31 to 40 of about 2,867,692 (324)

Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature

open access: yesPharmaceuticals, 2018
Prostaglandins and thromboxane are lipid signaling molecules deriving from arachidonic acid by the action of the cyclooxygenase isoenzymes COX-1 and COX-2.
A. Pannunzio, M. Coluccia
semanticscholar   +1 more source

The role of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide and interleukin-1 stimulated enterocyte prostanoid formation

open access: yesMediators of Inflammation, 1998
Lipopolysaccharide is an inflammatory agent and interleukin-1 is a cytokine. Their pro-inflammatory effects may be mediated by prostanoids produced by inducible cyclooxygenase-2.
W. E. Longo   +5 more
doaj   +1 more source

Cardiovascular Effects of the Cyclooxygenase Inhibitors [PDF]

open access: yesHypertension, 2007
Cyclooxyenase (COX)-2 selective inhibitors were developed to create a new class of nonsteroidal anti-inflammatory drugs (NSAIDs) with properties similar to those of nonselective NSAIDS but without their potential COX-1–mediated gastrointestinal toxicities.1,2 Studies of the various COX-2 selective inhibitors have shown that they are in fact associated ...
openaire   +3 more sources

Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.

open access: yesCurrent Medicinal Chemistry, 2018
Inflammation plays a crucial role in the development of many complex diseases and disorders including autoimmune diseases, metabolic syndrome, neurodegenerative diseases, and cardiovascular pathologies.
M. Ferrer   +6 more
semanticscholar   +1 more source

Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis

open access: yesBritish Journal of Cancer, 2014
Background:Esophageal adenocarcinoma (EAC) has high mortality and is increasing in incidence. Barrett’s esophagus (BE) increases the risk for EAC.
S. Zhang   +9 more
semanticscholar   +1 more source

Docking Study, Synthesis, and Anti-Inflammatory Potential of Some New Pyridopyrimidine-Derived Compounds

open access: yesJournal of Inflammation Research, 2022
Mohamed A Abdelgawad,1 Mohammad M Al-Sanea,1 Arafa Musa,2 Mohammed Elmowafy,3 Ashraf K El-Damasy,4 Amany A Azouz,5 Mohammed M Ghoneim,6 Rania R Bakr7 1Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 72341 ...
Abdelgawad MA   +7 more
doaj  

Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016).

open access: yesMedChemComm, 2017
Most drugs used to treat pain and inflammation act through inhibition of the enzymes prostaglandin G/H synthase, commonly known as cyclooxygenase (COX). Among these, the simultaneous inhibition of cyclooxygenase 1 (COX-1) would explain the unwanted side ...
G. Carullo, F. Galligano, F. Aiello
semanticscholar   +1 more source

Synthesis and Biological Evaluation of Gentiopicroside Derivatives as Novel Cyclooxygenase-2 Inhibitors with Anti-Inflammatory Activity

open access: yesDrug Design, Development and Therapy, 2023
Guojin Ren,1,* Qili Zhang,1,2,* Pengfei Xia,1– 4 Jie Wang,1 Pengxia Fang,1 Xiaojie Jin,1 Xuejing Peng,1– 4 Yanli Xu,1,5 Jian Zhang,1– 4 Lei Zhao1– 5 1Gansu University of Chinese Medicine, Lanzhou, 730000, People’s Republic of China; 2Northwest ...
Ren G   +9 more
doaj  

Assessment of Platelet Function in Traumatic Brain Injury—A Retrospective Observational Study in the Neuro-Critical Care Setting

open access: yesFrontiers in Neurology, 2018
BackgroundDespite seemingly functional coagulation, hemorrhagic lesion progression is a common and devastating condition following traumatic brain injury (TBI), stressing the need for new diagnostic techniques.
Caroline Lindblad   +7 more
doaj   +1 more source

Cyclooxygenase Inhibitors Derived from Thalidomide.

open access: yesChemInform, 2003
AbstractFor Abstract see ChemInform Abstract in Full Text.
Kazuo Nagasawa   +6 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy